骨关节炎药物市场规模、份额和增长分析（按药物类型、解剖结构、给药途径、销售管道、最终用途和地区）- 行业预测 2025-2032

2023 年骨关节炎治疗市场规模价值为 95 亿美元，预计将从 2024 年的 101.6 亿美元成长到 2032 年的 173.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

根据 2023 年 1 月 CDC 的资料，骨关节炎影响超过 3,250 万美国，预计市场将显着成长。盛行率的急剧上升，尤其是在老年人和女性中，凸显了对有效治疗的迫切需求。肌肉骨骼异常和荷尔蒙变化等因素会增加女性患病的风险，而女性中更为普遍的肥胖则进一步导致患病风险。随着该领域研究和开发的不断深入，创新的治疗方案不断涌现，尤其是透过关节内给药和缓解疾病的药物。由于这些进展和对骨关节炎的了解不断加深，市场预计会扩大，因此有明显的机会采取有针对性的干预措施来应对这一重大的健康挑战。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

骨关节炎药物市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• 关节内粘稠补充疗法治疗
• 非类固醇消炎剂
  • 萘普生
  • 阿斯匹灵
  • 双氯芬酸钠
  • Ibuprofen
  • 塞来昔布
  • 美洛康
  • Piroxicam
  • 酮洛芬
  • 其他 NSAID
• 止痛药
  • Duloxetine
  • 乙酰胺酚
• 皮质类固醇
• 其他的

骨关节炎药物市场规模（按解剖学和复合年增长率） (2025-2032)

• 市场概况
• 膝关节骨关节炎
• 髋关节骨关节炎
• 手部骨关节炎
• 其他的

骨关节炎治疗药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概况
• 肠外给药
  • 玻尿酸注射
  • 皮质类固醇注射
  • 富血小板血浆 (PRP) 注射
  • 胎盘组织基质（PTM）注射
  • 乙酰水杨酸（ASA）注射剂
  • 其他的
• 局部路线
• 口服

骨关节炎治疗药物市场规模（销售管道及复合年增长率）（2025-2032）

• 市场概况
• 处方药
• 非处方药

骨关节炎药物市场规模（依最终用途和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 其他的

骨关节炎治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Sanofi SA（France）
• Johnson & Johnson（USA）
• Eli Lilly and Company（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Flexion Therapeutics, Inc.（USA）
• Seikagaku Corporation（Japan）
• TissueGene, Inc.（South Korea）
• Anika Therapeutics, Inc.（USA）
• Ampio Pharmaceuticals, Inc.（USA）
• BioDelivery Sciences International, Inc.（USA）
• Bone Therapeutics SA（Belgium）
• Kolon TissueGene, Inc.（South Korea）
• Centrexion Therapeutics Corporation（USA）
• Kiniksa Pharmaceuticals, Ltd.（Bermuda）

结论和建议

Osteoarthritis Therapeutics Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The osteoarthritis market is poised for significant growth, with over 32.5 million Americans affected, according to January 2023 CDC data. This surge in prevalence, particularly among older adults and women, underscores the critical demand for effective therapies. Factors such as musculoskeletal abnormalities and hormonal changes contribute to the heightened risk in women, while obesity, which is more common among females, further predisposes them to the condition. As research and development in this area intensify, innovative treatment solutions, particularly through intra-articular drug administration and disease-modifying medications, are emerging. With the market expected to expand due to these advancements and a deeper understanding of osteoarthritis, there's a clear opportunity for targeted interventions that address this significant health challenge.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Therapeutics Market Segments Analysis

Global Osteoarthritis Therapeutics Market is segmented by Drug Type, Anatomy, Route of Administration, Sales Channel, End Use and region. Based on Drug Type, the market is segmented into Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids and Others. Based on Anatomy, the market is segmented into Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis and Others. Based on Route of Administration, the market is segmented into Parenteral Route, Topical Route and Oral Route. Based on Sales Channel, the market is segmented into Prescription Drugs and Over-the-Counter Drugs. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Therapeutics Market

The global osteoarthritis therapeutics market is poised for significant growth, particularly within the rapidly aging populations in developed regions like North America and Europe. As the number of elderly individuals rises, the prevalence of joint degenerative diseases also increases, leading to a greater need for effective treatment options. This surge in demand not only propels market growth but also fosters innovation within the therapeutic landscape, as pharmaceutical companies and researchers strive to develop novel and improved solutions for osteoarthritis management. Consequently, the combination of demographic trends and the corresponding healthcare needs creates a robust environment for market expansion.

Restraints in the Osteoarthritis Therapeutics Market

A significant restraint in the Osteoarthritis Therapeutics market stems from the potential side effects linked to traditional treatments like NSAIDs and corticosteroids. The extended use of these medications can result in serious complications, including gastrointestinal disorders and cardiovascular diseases. This adverse effect profile makes patients hesitant to rely on these conventional therapies, prompting them to explore alternative options instead. Consequently, the undesirable nature of these drugs hampers their widespread acceptance and limits their usage in the mainstream treatment of osteoarthritis, ultimately impacting market growth and development. As patients prioritize safety, the demand for safer, more effective alternatives continues to rise.

Market Trends of the Osteoarthritis Therapeutics Market

The Osteoarthritis Therapeutics market is witnessing a notable trend towards the rising adoption of minimally invasive treatments, such as viscosupplementation and biologic injections. These innovative therapies offer effective pain relief and enhance joint function while significantly minimizing recovery times compared to traditional surgical interventions. As patients increasingly seek alternatives that allow for quicker return to daily activities, and as healthcare providers recognize the benefits of these less invasive options, the demand for minimally invasive solutions in osteoarthritis management is expected to grow. This shift not only improves patient satisfaction but also reflects an evolving landscape in arthritis care that prioritizes efficiency and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Osteoarthritis Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Viscosupplementation Agents
• Nonsteroidal Anti-inflammatory Drugs
  • Naproxen
  • Aspirin
  • Diclofenac
  • Ibuprofen
  • Celecoxib
  • Meloxicam
  • Piroxicam
  • Ketoprofen
  • Other NSAIDs
• Analgesics
  • Duloxetine
  • Acetaminophen
• Corticosteroids
• Others

Global Osteoarthritis Therapeutics Market Size by Anatomy & CAGR (2025-2032)

• Market Overview
• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Others

Global Osteoarthritis Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Parenteral Route
  • Hyaluronic Acid Injections
  • Corticosteroid Injections
  • Platelet-rich Plasma (PRP) Injections
  • Placental Tissue Matrix (PTM) Injections
  • Acetylsalicylic Acid (ASA) Injections
  • Others
• Topical Route
• Oral Route

Global Osteoarthritis Therapeutics Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-the-Counter Drugs

Global Osteoarthritis Therapeutics Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Osteoarthritis Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • US
  • Canada
• Europe (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flexion Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seikagaku Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioDelivery Sciences International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bone Therapeutics SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kolon TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centrexion Therapeutics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiniksa Pharmaceuticals, Ltd. (Bermuda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations